Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, was submitted on May 19, 2026. The report serves to disseminate a press release dated May 19, 2026, to U.S. investors. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text contains only the cover page and exhibit index for the Form 6-K. It does not include the full text of the press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes
As the specific content of the press release (Exhibit 99.1) is not included in the input text, no material changes versus the prior comparable period can be identified from this document alone.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details regarding unusual items. These elements would be contained within the referenced press release, which is not provided in the source text.
Key Facts for Investor Verification
- Verify the full content of the press release dated May 19, 2026, referenced as Exhibit 99.1, as the summary data is absent from the cover page.
- Confirm the specific nature of the announcement (e.g., clinical trial results, partnership, financial update) by accessing the full exhibit.
- Note that the report is signed by Jonathan Dickinson, Chief Executive Officer, on May 19, 2026.